Fusions between dendritic cells and whole tumor cells as anticancer vaccines

Shigeo Koido Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan; Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan; Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, JapanCorrespondence[email protected]

Sadamu Homma Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Masato Okamoto Division of Cellular Signaling; Institute for Advanced Medical Research; Keio University School of Medicine; Tokyo, Japan

Yoshihisa Namiki Institute of Clinical Medicine and Research; The Jikei University School of Medicine; Tokyo, Japan

Kazuki Takakura Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Kan Uchiyama Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Mikio Kajihara Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Seiji Arihiro Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Hiroo Imazu Department of Endoscopy; The Jikei University School of Medicine; Tokyo, Japan

Hiroshi Arakawa Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan; Department of Endoscopy; The Jikei University School of Medicine; Tokyo, Japan

Shin Kan Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Hideo Komita Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan; Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Masaki Ito Department of Oncology, Institute of DNA Medicine; The Jikei University School of Medicine; Tokyo, Japan

Toshifumi Ohkusa Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

Jianlin Gong Department of Medicine; Boston University School of Medicine; Boston, MA USA

Hisao Tajiri Division of Gastroenterology and Hepatology; Department of Internal Medicine; The Jikei University School of Medicine; Tokyo, Japan

show all

Abstract

Various strategies have been developed to deliver tumor-associated antigens (TAAs) to dendritic cells (DCs). Among these, the fusion of DCs and whole cancer cells can process a broad array of TAAs, including hitherto unidentified molecules, and present them in complex with MHC Class I and II molecules and in the context of co-stimulatory signals. DC-cancer cell fusions have been shown to stimulate potent antitumor immune responses in animal models. In early clinical trials, however, the antitumor effects of DC-cancer cell fusions are not as vigorous as in preclinical settings. This mini-review summarizes recent advances in anticancer vaccines based on DC-cancer cell fusions.

Keywords: :

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Fusions between dendritic cells and whole tumor cells as anticancer vaccines

Information for

Open access

Opportunities

Help and information

Fusions between dendritic cells and whole tumor cells as anticancer vaccines

Abstract

Disclosure of Potential Conflicts of Interest

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date

Your download is now in progress and you may close this window

Login or register to access this feature